Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Annie Frimm"'
Autor:
Dennis E. Hruby, Paul G Long, Jarasvech Chinsangaram, Annie Frimm, Candace Lovejoy, Biswajit Maiti, Eric A. Rose, Ingrid Meara, Kady M. Honeychurch, Douglas W. Grosenbach
Publikováno v:
The New England journal of medicine
Smallpox was declared eradicated in 1980, but variola virus (VARV), which causes smallpox, still exists. There is no known effective treatment for smallpox; therefore, tecovirimat is being developed as an oral smallpox therapy. Because clinical trial
Autor:
Janet M. Leeds, Robert Jordan, Nastya Kassir, Nathalie H. Gosselin, Frederique Fenneteau, Dennis E. Hruby, J.F. Marier, Shanthakumar R. Tyavanagimatt, Doug Grosenbach, Kady M. Honeychurch, Yali Chen, Jarasvech Chinsangaram, Annie Frimm, Mohamad Samer Mouksassi
Publikováno v:
Antimicrobial agents and chemotherapy. 57(3)
Although smallpox has been eradicated, the United States government considers it a “material threat” and has funded the discovery and development of potential therapeutic compounds. As reported here, the human efficacious dose for one of these co
Autor:
Jean M. Clarke, Michael L. Corrado, Tove' C. Bolken, Margaret Pickens, Kevin F. Jones, Shanthakumar R. Tyavanagimatt, Thomas Marbury, Jarasvech Chinsangaram, Deborah Tien, Robert Jordan, Annie Frimm, Patrick Landis, Dennis E. Hruby
Publikováno v:
Antimicrobial agents and chemotherapy. 54(6)
ST-246, a novel compound that inhibits egress of orthopoxvirus from infected cells, is being evaluated as a treatment for pathogenic orthopoxvirus infections in humans. This phase I, double-blind, randomized, placebo-controlled, escalating multiple-d
Autor:
John W. Huggins, Josh Shamblin, Jarasvech Chinsangaram, Shanthakumar R. Tyavanagimatt, Adams Amantana, Arthur J. Goff, Annie Frimm, Lisa E. Hensley, Wendy Johnson, Eric M. Mucker, Chelsea M. Byrd, Carly Wlazlowski, Robert Jordan, Tove' C. Bolken, Dennis E. Hruby, Michael L. Corrado, Nancy A. Twenhafel, Jennifer Chapman
Therapeutics for the treatment of pathogenic orthopoxvirus infections are being sought. In the absence of patients with disease, animal models of orthopoxvirus disease are essential for evaluation of the efficacies of antiviral drugs and establishmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d562cf716ca12f09e5ddd8a84d7a12
https://europepmc.org/articles/PMC2681496/
https://europepmc.org/articles/PMC2681496/
Autor:
Michael L. Corrado, Shanthakumar R. Tyavanagimatt, Tove' C. Bolken, Josef Strasser, Kevin F. Jones, Deborah Tien, Dennis E. Hruby, Annie Frimm, Robert Jordan, Phoebe G. Strome
Publikováno v:
Antiviral Research. 78:A32
ST-246 is a novel, potent orthopoxvirus egress inhibitor that is being developed to treat pathogenic orthopoxvirus infections of humans. This phase I, double-blind, randomized, placebo-controlled single ascending dose study (first time with humans) w